@article{c1fdd50ebb2741fe83d91c6fa1053323,
title = "Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study",
abstract = "Carboxymethyl-lysine is an advanced glycation end product that is detectable in the serum. Higher carboxymethyl-lysine levels have been associated with increased risk of coronary heart disease, stroke and cardiovascular mortality. We determined whether high carboxymethyl-lysine levels are also associated with the risk of peripheral artery disease in Cardiovascular Health Study participants who were all aged 65 years and older at baseline. Multivariate Cox proportional hazards models were used to determine the association of baseline carboxymethyl-lysine levels with incident peripheral artery disease in 3267 individuals followed for a median length of 10.0 years. A total of 157 cases of incident peripheral artery disease occurred during follow-up. No significant relationship between carboxymethyl-lysine and risk of peripheral artery disease was found (hazard ratio per standard deviation increment = 1.03; 95% confidence interval = 0.87, 1.23).",
keywords = "Advanced glycation end products, ankle–brachial index, inflammation, peripheral artery disease",
author = "Garg, {Parveen K.} and Biggs, {Mary L.} and Joshua Barzilay and Luc Djousse and Calvin Hirsch and Ix, {Joachim H.} and Kizer, {Jorge R.} and Tracy, {Russell P.} and Newman, {Anne B.} and Siscovick, {David S.} and Mukamal, {Kenneth J.}",
note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by contract numbers HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086 and grant numbers U01HL080295, U01HL130114 and R01HL094555 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by contract numbers HHSN26 8201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086 and grant numbers U01HL080295, U01HL130114 and R01HL094555 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. Publisher Copyright: {\textcopyright} The Author(s) 2019.",
year = "2019",
month = sep,
day = "1",
doi = "10.1177/1479164119847481",
language = "English (US)",
volume = "16",
pages = "483--485",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications Ltd",
number = "5",
}
